European Commission approves use of Ameluz® for the treatment of actinic keratosis on extremities and trunk/neck
March 10, 2020 11:00 ET
|
Biofrontera AG
Leverkusen, Germany, March 10, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that...
Biofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA
March 25, 2019 10:00 ET
|
Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera Inc., USA (“Biofrontera”), a wholly owned subsidiary of Biofrontera AG (NASDAQ ticker...
Biofrontera Reports Positive Phase III Results with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
March 20, 2019 10:50 ET
|
Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical...